ES2409054T3 - Antagonistas de la vía Hedgehog de ftalazina disubstituida - Google Patents

Antagonistas de la vía Hedgehog de ftalazina disubstituida Download PDF

Info

Publication number
ES2409054T3
ES2409054T3 ES10726756T ES10726756T ES2409054T3 ES 2409054 T3 ES2409054 T3 ES 2409054T3 ES 10726756 T ES10726756 T ES 10726756T ES 10726756 T ES10726756 T ES 10726756T ES 2409054 T3 ES2409054 T3 ES 2409054T3
Authority
ES
Spain
Prior art keywords
cancer
pharmaceutically acceptable
methyl
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10726756T
Other languages
English (en)
Spanish (es)
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Wilson (Nee Takakuwa), Takako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2409054T3 publication Critical patent/ES2409054T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
ES10726756T 2009-06-19 2010-06-15 Antagonistas de la vía Hedgehog de ftalazina disubstituida Active ES2409054T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
US218628P 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
ES2409054T3 true ES2409054T3 (es) 2013-06-24

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10726756T Active ES2409054T3 (es) 2009-06-19 2010-06-15 Antagonistas de la vía Hedgehog de ftalazina disubstituida

Country Status (36)

Country Link
US (2) US8273742B2 (US07846941-20101207-C00217.png)
EP (1) EP2443104B1 (US07846941-20101207-C00217.png)
JP (1) JP5596139B2 (US07846941-20101207-C00217.png)
KR (1) KR101389165B1 (US07846941-20101207-C00217.png)
CN (1) CN102459233B (US07846941-20101207-C00217.png)
AR (1) AR077014A1 (US07846941-20101207-C00217.png)
AU (1) AU2010260244B2 (US07846941-20101207-C00217.png)
BR (1) BRPI1011601A2 (US07846941-20101207-C00217.png)
CA (1) CA2764542C (US07846941-20101207-C00217.png)
CL (1) CL2011003147A1 (US07846941-20101207-C00217.png)
CO (1) CO6480932A2 (US07846941-20101207-C00217.png)
CR (1) CR20110658A (US07846941-20101207-C00217.png)
DK (1) DK2443104T3 (US07846941-20101207-C00217.png)
DO (1) DOP2011000386A (US07846941-20101207-C00217.png)
EA (1) EA019059B1 (US07846941-20101207-C00217.png)
EC (1) ECSP11011541A (US07846941-20101207-C00217.png)
ES (1) ES2409054T3 (US07846941-20101207-C00217.png)
HK (1) HK1164872A1 (US07846941-20101207-C00217.png)
HN (1) HN2011003139A (US07846941-20101207-C00217.png)
HR (1) HRP20130408T1 (US07846941-20101207-C00217.png)
IL (1) IL216599A (US07846941-20101207-C00217.png)
JO (1) JO2931B1 (US07846941-20101207-C00217.png)
MA (1) MA33363B1 (US07846941-20101207-C00217.png)
MX (1) MX2011014029A (US07846941-20101207-C00217.png)
MY (1) MY156667A (US07846941-20101207-C00217.png)
NZ (1) NZ596882A (US07846941-20101207-C00217.png)
PE (1) PE20121050A1 (US07846941-20101207-C00217.png)
PL (1) PL2443104T3 (US07846941-20101207-C00217.png)
PT (1) PT2443104E (US07846941-20101207-C00217.png)
SG (1) SG177289A1 (US07846941-20101207-C00217.png)
SI (1) SI2443104T1 (US07846941-20101207-C00217.png)
TN (1) TN2011000627A1 (US07846941-20101207-C00217.png)
TW (1) TWI385165B (US07846941-20101207-C00217.png)
UA (1) UA106755C2 (US07846941-20101207-C00217.png)
WO (1) WO2010147917A1 (US07846941-20101207-C00217.png)
ZA (1) ZA201108587B (US07846941-20101207-C00217.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588001A (en) * 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
DK2364185T3 (da) * 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
CN102216292B (zh) * 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CA3017411A1 (en) 2016-03-15 2017-09-21 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
EP3624798A1 (en) 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
AU2021360767A1 (en) * 2020-10-13 2023-04-27 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (US07846941-20101207-C00217.png) * 1977-06-03 1981-03-07 Pfizer
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
DE60016402T2 (de) 1999-06-08 2005-10-27 Lorantis Ltd. Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
KR20040031782A (ko) * 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
CA2483311A1 (en) * 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
AU2005260102A1 (en) 2004-05-08 2006-01-12 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
PL1789390T3 (pl) 2004-09-02 2012-04-30 Genentech Inc Pirydylowe inhibitory szlaku sygnałowego hedgehog
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
US8592463B2 (en) * 2007-12-13 2013-11-26 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
NZ588001A (en) * 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010017240A2 (en) * 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
DK2364185T3 (da) 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
CN102216292B (zh) 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
CN102459233B (zh) 2014-07-02
NZ596882A (en) 2013-08-30
CA2764542A1 (en) 2010-12-23
KR101389165B1 (ko) 2014-04-24
MA33363B1 (fr) 2012-06-01
WO2010147917A1 (en) 2010-12-23
CR20110658A (es) 2012-02-20
DOP2011000386A (es) 2012-02-29
PT2443104E (pt) 2013-05-07
JO2931B1 (en) 2015-09-15
DK2443104T3 (da) 2013-05-06
EA201270049A1 (ru) 2012-05-30
CA2764542C (en) 2013-09-10
IL216599A (en) 2015-09-24
US8273742B2 (en) 2012-09-25
HN2011003139A (es) 2013-07-29
US9000023B2 (en) 2015-04-07
PE20121050A1 (es) 2012-08-09
JP5596139B2 (ja) 2014-09-24
AR077014A1 (es) 2011-07-27
HK1164872A1 (en) 2012-09-28
PL2443104T3 (pl) 2013-08-30
SG177289A1 (en) 2012-02-28
CN102459233A (zh) 2012-05-16
AU2010260244B2 (en) 2013-09-05
US20100324048A1 (en) 2010-12-23
MY156667A (en) 2016-03-15
CO6480932A2 (es) 2012-07-16
UA106755C2 (uk) 2014-10-10
HRP20130408T1 (en) 2013-06-30
TW201113268A (en) 2011-04-16
KR20120024783A (ko) 2012-03-14
IL216599A0 (en) 2012-03-01
TN2011000627A1 (en) 2013-05-24
CL2011003147A1 (es) 2012-07-20
EP2443104A1 (en) 2012-04-25
JP2012530705A (ja) 2012-12-06
ECSP11011541A (es) 2012-01-31
AU2010260244A1 (en) 2012-01-19
US20120316174A1 (en) 2012-12-13
SI2443104T1 (sl) 2013-07-31
ZA201108587B (en) 2013-05-29
BRPI1011601A2 (pt) 2016-03-22
MX2011014029A (es) 2012-02-21
EP2443104B1 (en) 2013-04-17
EA019059B1 (ru) 2013-12-30
TWI385165B (zh) 2013-02-11

Similar Documents

Publication Publication Date Title
ES2409054T3 (es) Antagonistas de la vía Hedgehog de ftalazina disubstituida
CA2743483C (en) Tetrasubstituted pyridazine hedgehog pathway antagonists
ES2418479T3 (es) Antagonistas de la ruta erizo de ftalazinas disustituidas
ES2446307T3 (es) Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog